The Miriam Hospital is now recruiting patients for a study to test the effectiveness of a new vaccine to treat Clostridium difficile infection (CDI).
CDI, commonly known as C. diff, is a severe intestinal disease caused by bacteria. Symptoms range from mild diarrhea to life-threatening bowel disease and
often include dehydration, abdominal pain and spasms. Risk of C. diff infection increases with age, antibiotic treatments and time spent in hospitals or nursing homes--where multiple cases can lead to infection outbreaks. Each year, 14,000 American deaths are attributed to C. diff, while 500,000 Americans are hospitalized each year with C. diff infection.
The fight against C. diff has become a global effort among researchers because it is such a significant health care concern. Now, the American Food and
Drug administration has approved a Phase 3 research trial to study the efficacy of a new vaccine called “Cdiffense.”
The Miriam Hospital is one of many sites worldwide taking part in this important research study. The hospital is currently recruiting volunteers to
evaluate the effects of the vaccine for the prevention of CDI episodes in at-risk individuals. Individuals who are age 50 or older and planning
hospitalization of more than 72 hours for surgical procedures or who have had at least two hospital stays, each lasting more than 72 hours, and have
received systemic antibiotics in the past year, may qualify to participate.
To inquire about your eligibility or for more information, please contact Pamela Poethke, RN, at 401-793-4971.